Drug company Eli Lilly is looking for 300K SF in South San Francisco, a space more than double the size of the company’s existing 130K SF footprint in the city.

The company looked at space owned by Alexandria Real Estate Equities, Boston Properties, Kilroy Realty and BioMed Realty, according to the San Francisco Business Times, which first reported Eli Lilly's intentions.

"While we regularly evaluate our strategy regarding all Lilly sites worldwide, we do not share the details of those strategic evaluations," the spokesperson from Eli Lilly said in comments to the San Francisco Business Times.

Lilly is reportedly eyeing the 681 Gateway campus for expansion. The company launched a biotech incubator at 681 Gateway Blvd. in 2019.

The pharma giant has made headlines in recent months, saying in August that an abortion ban in its home state of Indiana might cause it to reassess its expansion plans.

“Given this new law, we will be forced to plan for more employment growth outside our home state,” the company said in a statement at the time.

And on Monday, the company was sued by the U.S. Equal Employment Opportunity Commission for alleged age discrimination.

Life sciences continues to be one of the hotter asset classes in the Bay Area, with the South San Francisco and parts of the South Bay being prime locations for the segment. Baylands Development Inc. recently put forward plans to build a mixed-use life sciences and hotel facility spanning 1M SF in Brisbane, California.